- Markets
- Healthcare
- COLINZ
COLINZ
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
This data is currently unavailable for this company.
Events:
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Colinz Laboratories do?
Colinz Laboratories Ltd manufactures a wide range of pharmaceutical formulations, including tablets, capsules, creams, and veterinary and nutraceutical products. They also provide turnkey projects for pharma formulation plants and technical know-how transfer.
Who are the competitors of Colinz Laboratories?
Colinz Laboratories major competitors are Link Pharma Chem, Venmax Drugs&Pharma, Desh Rakshak Aushdh, Norris Medicines, Parmax Pharma, Saroja Pharma Ind, Beryl Drugs. Market Cap of Colinz Laboratories is ₹15 Crs. While the median market cap of its peers are ₹16 Crs.
Is Colinz Laboratories financially stable compared to its competitors?
Colinz Laboratories seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Colinz Laboratories pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Colinz Laboratories latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Colinz Laboratories allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Colinz Laboratories balance sheet?
Balance sheet of Colinz Laboratories is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Colinz Laboratories improving?
Yes, profit is increasing. The profit of Colinz Laboratories is ₹0.49 Crs for Mar 2024, ₹0.46 Crs for Mar 2023 and ₹0.34 Crs for Mar 2022
Is the debt of Colinz Laboratories increasing or decreasing?
Yes, The debt of Colinz Laboratories is increasing. Latest debt of Colinz Laboratories is -₹7.23 Crs as of Sep-24. This is greater than Mar-24 when it was -₹13.43 Crs.
Is Colinz Laboratories stock expensive?
Yes, Colinz Laboratories is expensive. Latest PE of Colinz Laboratories is 32.07, while 3 year average PE is 28.31. Also latest EV/EBITDA of Colinz Laboratories is 14.91 while 3yr average is 9.72.
Has the share price of Colinz Laboratories grown faster than its competition?
Colinz Laboratories has given better returns compared to its competitors. Colinz Laboratories has grown at ~45.0% over the last 1yrs while peers have grown at a median rate of 25.82%
Is the promoter bullish about Colinz Laboratories?
Promoters seem not to be bullish about the company and have been selling shares in the open market. Latest quarter promoter holding in Colinz Laboratories is 65.94% and last quarter promoter holding is 66.0%
Are mutual funds buying/selling Colinz Laboratories?
There is Insufficient data to gauge this.